Similar Search Results

Cost Effectiveness of Rituximab for Non-Hodgkin’s Lymphoma

Auweiler, Philipp; Müller, Dirk; Stock, Stephanie; … - In: PharmacoEconomics 30 (2012) 7, pp. 537-549

Adding rituximab to standard chemotherapy is considered a cost-effective treatment option for NHL. However, the results of the analyses should be interpreted with caution due to methodological limitations. </AbstractSection> Copyright Springer International Publishing AG 2012

Persistent link: https://www.econbiz.de/10011001563

Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer

Müller, Dirk; Danner, Marion C.; Schmutzler, Rita; … - In: The European journal of health economics : HEPAC ; … 20 (2019) 5, pp. 739-750

Persistent link: https://www.econbiz.de/10012061271

Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation

Müller, Dirk; Danner, Marion C.; Rhiem, Kerstin E. M.; … - In: The European journal of health economics : HEPAC ; … 19 (2018) 3, pp. 341-353

Persistent link: https://www.econbiz.de/10011946572

Risikocontrolling im Kreditgeschäft als Bestandteil eines ganzheitlichen Risikomanagementkonzeptes

Hertenstein, Karl-Heinz; Müller, Dirk; Oehme, Mario - 2002 - 1. [Aufl.]

Persistent link: https://www.econbiz.de/10001713011